Drug intelligence / Profile preview

PGN-EDO45

Development stage: Unknown
Lead developer: PepGen
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

PGN-EDO45 is an oligonucleotide therapeutic developed by PepGen, leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The EDO platform technology, which underpins PepGen's entire pipeline, was originally developed by researchers at the University of Oxford and the Medical Research Council (MRC). PepGen was founded to develop and commercialize this technology for severe neuromuscular and neurological diseases.

Targets

DMD (Dystrophin)

Beyond the preview

Go deeper on PGN-EDO45.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGN-EDO45.

Explore the full profile